Key result
Rivaroxaban plus aspirin reduced cardiovascular death, myocardial infarction, or stroke compared to aspirin alone in patients with diabetes (HR 0.74, P=0.002) and without diabetes (HR 0.77, P=0.005).
Why the study?
Patients with established coronary artery disease or peripheral artery disease often have diabetes mellitus, placing them at high risk of future vascular events.
Does rivaroxaban plus aspirin reduce the composite of cardiovascular death, myocardial infarction, or stroke in patients with established coronary or peripheral artery disease?
RCT (n=27,395)
Does rivaroxaban plus aspirin reduce the composite of cardiovascular death, myocardial infarction, or stroke in patients with established coronary or peripheral artery disease?
Hazard Ratio: 0.74
Absolute Risk Reduction: 2.3%
p-value: p=0.002
In patients with stable atherosclerosis, adding rivaroxaban 2.5 mg twice daily to aspirin provides consistent relative cardiovascular benefits regardless of diabetes status, with greater absolute benefits in those with diabetes.
No takes yet. Share an insight, caveat, or question.
Supports rivaroxaban plus aspirin in stable atherosclerosis; confirms consistent relative benefit irrespective of diabetes status.
Bhatt et al. (2020) conducted an RCT in Coronary artery disease or peripheral artery disease (n=27,395). Rivaroxaban plus aspirin vs. Placebo plus aspirin was evaluated on Composite of cardiovascular death, myocardial infarction, or stroke (HR 0.74, p=0.002). Rivaroxaban plus aspirin reduced cardiovascular death, myocardial infarction, or stroke compared to aspirin alone in patients with diabetes (HR 0.74, P=0.002) and without diabetes (HR 0.77, P=0.005).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: